Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know

Expert faculty discuss the latest data on using SGLT2 inhibitors to reduce HF risk in patients with T2D
Jennifer B. Green, MD
Mikhail N. Kosiborod, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.16 MB
Released: June 7, 2021


Provided by the Endocrine Society

For questions about content or obtaining CME credit, please contact the Endocrine Society at www.education.endocrine.org/contact.

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company

Related Content

Learn about obesity management for long-term weight loss and CVD risk reduction; focus on new and emerging incretin therapies, eg, GLP-1 agonists, from Clinical Care Options (CCO)

person default Fatima Cody Stanford, MD, MPH, MPA, MBA Released: June 8, 2021

Jenny Tong, MD, MPH, answers questions about GLP-1 receptor agonists for weight loss treatment duration and weight stability and use in patients with obesity and related comorbidities

Jenny Tong, MD, MPH Released: May 4, 2021

Randy Seeley, PhD: Thoughts on body weight set points and how they affect obesity and its management from Clinical Care Options (CCO)

Randy J. Seeley, PhD Released: May 4, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.